Skip to content
OpenCapital
Get started

Kairos Pharma KAPA Q1 2026 Annual earnings

Reported May 13, 2026 · Before market open

Diluted EPS-$0.08Miss by $0.01
EPS estimate-$0.07

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.09

Versus estimates

Diluted EPS

Q1 2026-$0.08Miss by $0.01
Q4 2025-$0.07Miss by $0.05Q3 2025-$0.07Beat by $0.03Q2 2025-$0.08Miss by $0.02Q1 2025-$0.08Miss by $0.03Q4 2024-$0.09Miss by $0.03

Ask the moment Kairos Pharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kairos Pharma report Q1 2026 earnings?
Kairos Pharma (KAPA) reported Q1 2026 earnings on May 13, 2026 before market open.
What were Kairos Pharma's Q1 2026 revenue and EPS?
Kairos Pharma reported diluted EPS of $-0.08 for Q1 2026.
Did Kairos Pharma beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.07 by $0.01.
How did Kairos Pharma's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 0.0% from $-0.08.
Where can I find Kairos Pharma's Q1 2026 SEC filings?
You can read the 10-K periodic report (0001493152-26-014159) directly on SEC EDGAR. The filing index links above go to sec.gov.